X線基準を満たさない体軸性脊椎関節炎におけるゴリムマブの有効性と安全性: 休薬と再治療 (GO-BACK)
Rheumatology (Oxford) 2023;62(11):3601–3609 doi: 10.1093/rheumatology/kead112
This study highlighted that continued treatment with Golimumab (GLM) QMT or GLM Q2MT was superior to placebo. The GO-BACK study was designed to evaluate the efficacy and safety of golimumab treatment withdrawal in adults with nr-axSpA who demonstrate inactive disease during a 10-month open label GLM run-in.
Overall, GLM QMT was most beneficial in reducing the incidence of disease flares, and improving clinical signs and symptoms of nr-axSpA compared with treatment withdrawal. GLM was generally well tolerated, and safety results were consistent with the known safety profile of GLM.
Keywords:
